Now showing items 1-20 of 24

    • Accuracy of screening women at familial risk of breast cancer without a known gene mutation: Individual patient data meta-analysis. 

      Phi, X-A; Houssami, N; Hooning, MJ; Riedl, CC; Leach, MO; Sardanelli, F; Warner, E; Trop, I; Saadatmand, S; Tilanus-Linthorst, MMA; Helbich, TH; van den Heuvel, ER; de Koning, HJ; Obdeijn, I-M; de Bock, GH (2017-11)
      Women with a strong family history of breast cancer (BC) and without a known gene mutation have an increased risk of developing BC. We aimed to investigate the accuracy of screening using annual mammography with or without ...
    • Assessment of the contribution of the IHC4+C score to decision making in clinical practice in early breast cancer. 

      Barton, S; Zabaglo, L; A'Hern, R; Turner, N; Ferguson, T; O'Neill, S; Hills, M; Smith, I; Dowsett, M (2012-05)
      BACKGROUND:The immunohistochemical (IHC) 4+C score is a cost-effective prognostic tool that uses clinicopathologic factors and four standard IHC assays: oestrogen receptor (ER), PR, HER2 and Ki67. We assessed its utility ...
    • Baseline results from the UK SIGNIFY study: a whole-body MRI screening study in TP53 mutation carriers and matched controls. 

      Saya, S; Killick, E; Thomas, S; Taylor, N; Bancroft, EK; Rothwell, J; Benafif, S; Dias, A; Mikropoulos, C; Pope, J; Chamberlain, A; Gunapala, R; SIGNIFY Study Steering Committee; Izatt, L; Side, L; Walker, L; Tomkins, S; Cook, J; Barwell, J; Wiles, V; Limb, L; Eccles, D; Leach, MO; Shanley, S; Gilbert, FJ; Hanson, H; Gallagher, D; Rajashanker, B; Whitehouse, RW; Koh, D-M; Sohaib, SA; Evans, DG; Eeles, RA (2017-07)
      In the United Kingdom, current screening guidelines for TP53 germline mutation carriers solely recommends annual breast MRI, despite the wide spectrum of malignancies typically seen in this group. This study sought to ...
    • Baseline Surveillance in Li-Fraumeni Syndrome Using Whole-Body Magnetic Resonance Imaging: A Meta-analysis. 

      Ballinger, ML; Best, A; Mai, PL; Khincha, PP; Loud, JT; Peters, JA; Achatz, MI; Chojniak, R; Balieiro da Costa, A; Santiago, KM; Garber, J; O'Neill, AF; Eeles, RA; Evans, DG; Bleiker, E; Sonke, GS; Ruijs, M; Loo, C; Schiffman, J; Naumer, A; Kohlmann, W; Strong, LC; Bojadzieva, J; Malkin, D; Rednam, SP; Stoffel, EM; Koeppe, E; Weitzel, JN; Slavin, TP; Nehoray, B; Robson, M; Walsh, M; Manelli, L; Villani, A; Thomas, DM; Savage, SA (2017-12)
      Importance:Guidelines for clinical management in Li-Fraumeni syndrome, a multiple-organ cancer predisposition condition, are limited. Whole-body magnetic resonance imaging (WBMRI) may play a role in surveillance of this ...
    • Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. 

      Merker, JD; Oxnard, GR; Compton, C; Diehn, M; Hurley, P; Lazar, AJ; Lindeman, N; Lockwood, CM; Rai, AJ; Schilsky, RL; Tsimberidou, AM; Vasalos, P; Billman, BL; Oliver, TK; Bruinooge, SS; Hayes, DF; Turner, NC (2018-10)
      PURPOSE.—:Clinical use of analytical tests to assess genomic variants in circulating tumor DNA (ctDNA) is increasing. This joint review from the American Society of Clinical Oncology and the College of American Pathologists ...
    • Circulating tumor DNA-From bench to bedside. 

      Lim, JSJ; Janku, F; Yap, TA (2017-05)
      In the era of personalized medicine, tumor sampling is paramount to enable the assessment of actionable molecular aberrations to help rationalize and guide treatment decisions. Longitudinal tracking of such aberrations may ...
    • Comparison of optimised endovaginal vs external array coil T2-weighted and diffusion-weighted imaging techniques for detecting suspected early stage (IA/IB1) uterine cervical cancer. 

      Downey, K; Attygalle, AD; Morgan, VA; Giles, SL; MacDonald, A; Davis, M; Ind, TEJ; Shepherd, JH; deSouza, NM (2016-04)
      To compare sensitivity and specificity of endovaginal versus external-array coil T2-W and T2-W + DWI for detecting and staging small cervical tumours.Optimised endovaginal and external array coil MRI at 3.0-T was done ...
    • Consensus Statement on Circulating Biomarkers for Advanced Prostate Cancer. 

      Sumanasuriya, S; Omlin, A; Armstrong, A; Attard, G; Chi, KN; Bevan, CL; Shibakawa, A; IJzerman, MJ; De Laere, B; Lolkema, M; Lorente, D; Luo, J; Mehra, N; Olmos, D; Scher, H; Soule, H; Stoecklein, NH; Terstappen, LWMM; Waugh, D; de Bono, JS (2018-06)
      CONTEXT:In advanced prostate cancer (PC), there is increasing investigation of circulating biomarkers, including quantitation and characterization of circulating tumour cells and cell-free nucleic acids, for therapeutic ...
    • A Cost-Effectiveness Evaluation of Germline BRCA1 and BRCA2 Testing in UK Women with Ovarian Cancer. 

      Eccleston, A; Bentley, A; Dyer, M; Strydom, A; Vereecken, W; George, A; Rahman, N (2017-04)
      OBJECTIVES:To evaluate the long-term cost-effectiveness of germline BRCA1 and BRCA2 (collectively termed "BRCA") testing in women with epithelial ovarian cancer, and testing for the relevant mutation in first- and second-degree ...
    • Critical research gaps and recommendations to inform research prioritisation for more effective prevention and improved outcomes in colorectal cancer. 

      Lawler, M; Alsina, D; Adams, RA; Anderson, AS; Brown, G; Fearnhead, NS; Fenwick, SW; Halloran, SP; Hochhauser, D; Hull, MA; Koelzer, VH; McNair, AGK; Monahan, KJ; Näthke, I; Norton, C; Novelli, MR; Steele, RJC; Thomas, AL; Wilde, LM; Wilson, RH; Tomlinson, I; Bowel Cancer UK Critical Research Gaps in Colorectal Cancer Initiative (2018-01)
      OBJECTIVE:Colorectal cancer (CRC) leads to significant morbidity/mortality worldwide. Defining critical research gaps (RG), their prioritisation and resolution, could improve patient outcomes. DESIGN:RG analysis was conducted ...
    • Effect of population breast screening on breast cancer mortality up to 2005 in England and Wales: an individual-level cohort study. 

      Johns, LE; Coleman, DA; Swerdlow, AJ; Moss, SM (2017-01)
      BACKGROUND:Population breast screening has been implemented in the UK for over 25 years, but the size of benefit attributable to such programmes remains controversial. We have conducted the first individual-based cohort ...
    • Genetic predisposition to prostate cancer. 

      Benafif, S; Eeles, R (2016-12)
      INTRODUCTION:Prostate cancer (PrCa) is the commonest non-cutaneous cancer in men in the UK. Epidemiological evidence as well as twin studies points towards a genetic component contributing to aetiology. SOURCES OF DATA:Key ...
    • Modeling the prevention of colorectal cancer from the combined impact of host and behavioral risk factors. 

      Frampton, M; Houlston, RS (2017-03)
      This study investigated the utility of modeling modifiable lifestyle risk factors in addition to genetic variation in colorectal cancer (CRC) screening/prevention.We derived a polygenic risk score for CRC susceptibility ...
    • National implementation of multi-parametric magnetic resonance imaging for prostate cancer detection - recommendations from a UK consensus meeting. 

      Brizmohun Appayya, M; Adshead, J; Ahmed, HU; Allen, C; Bainbridge, A; Barrett, T; Giganti, F; Graham, J; Haslam, P; Johnston, EW; Kastner, C; Kirkham, APS; Lipton, A; McNeill, A; Moniz, L; Moore, CM; Nabi, G; Padhani, AR; Parker, C; Patel, A; Pursey, J; Richenberg, J; Staffurth, J; van der Meulen, J; Walls, D; Punwani, S (2018-07)
      OBJECTIVES:To identify areas of agreement and disagreement in the implementation of multi-parametric magnetic resonance imaging (mpMRI) of the prostate in the diagnostic pathway. MATERIALS AND METHODS:Fifteen UK experts ...
    • Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts. 

      Seibert, TM; Fan, CC; Wang, Y; Zuber, V; Karunamuni, R; Parsons, JK; Eeles, RA; Easton, DF; Kote-Jarai, Z; Al Olama, AA; Garcia, SB; Muir, K; Grönberg, H; Wiklund, F; Aly, M; Schleutker, J; Sipeky, C; Tammela, TL; Nordestgaard, BG; Nielsen, SF; Weischer, M; Bisbjerg, R; Røder, MA; Iversen, P; Key, TJ; Travis, RC; Neal, DE; Donovan, JL; Hamdy, FC; Pharoah, P; Pashayan, N; Khaw, K-T; Maier, C; Vogel, W; Luedeke, M; Herkommer, K; Kibel, AS; Cybulski, C; Wokolorczyk, D; Kluzniak, W; Cannon-Albright, L; Brenner, H; Cuk, K; Saum, K-U; Park, JY; Sellers, TA; Slavov, C; Kaneva, R; Mitev, V; Batra, J; Clements, JA; Spurdle, A; Teixeira, MR; Paulo, P; Maia, S; Pandha, H; Michael, A; Kierzek, A; Karow, DS; Mills, IG; Andreassen, OA; Dale, AM; PRACTICAL Consortium* (2018-01-10)
      OBJECTIVES:To develop and validate a genetic tool to predict age of onset of aggressive prostate cancer (PCa) and to guide decisions of who to screen and at what age. DESIGN:Analysis of genotype, PCa status, and age to ...
    • The PROFILE Feasibility Study: Targeted Screening of Men With a Family History of Prostate Cancer. 

      Castro, E; Mikropoulos, C; Bancroft, EK; Dadaev, T; Goh, C; Taylor, N; Saunders, E; Borley, N; Keating, D; Page, EC; Saya, S; Hazell, S; Livni, N; deSouza, N; Neal, D; Hamdy, FC; Kumar, P; Antoniou, AC; Kote-Jarai, Z; PROFILE Study Steering Committee; Eeles, RA (2016-06)
      A better assessment of individualized prostate cancer (PrCa) risk is needed to improve screening. The use of the prostate-specific antigen (PSA) level for screening in the general population has limitations and is not ...
    • Prostate Cancer Germline Variations and Implications for Screening and Treatment. 

      Dias, A; Kote-Jarai, Z; Mikropoulos, C; Eeles, R (2018-09-04)
      Prostate cancer (PCa) is a highly heritable disease, and rapid evolution of sequencing technologies has enabled marked progression of our understanding of its genetic inheritance. A complex polygenic model that involves ...
    • Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 

      Horwich, A; Parker, C; Bangma, C; Kataja, V; ESMO Guidelines Working Group (2010-05)
    • Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 

      Horwich, A; Parker, C; de Reijke, T; Kataja, V; ESMO Guidelines Working Group (2013-10)
    • Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition. 

      Mikropoulos, C; Selkirk, CGH; Saya, S; Bancroft, E; Vertosick, E; Dadaev, T; Brendler, C; Page, E; Dias, A; Evans, DG; Rothwell, J; Maehle, L; Axcrona, K; Richardson, K; Eccles, D; Jensen, T; Osther, PJ; van Asperen, CJ; Vasen, H; Kiemeney, LA; Ringelberg, J; Cybulski, C; Wokolorczyk, D; Hart, R; Glover, W; Lam, J; Taylor, L; Salinas, M; Feliubadaló, L; Oldenburg, R; Cremers, R; Verhaegh, G; van Zelst-Stams, WA; Oosterwijk, JC; Cook, J; Rosario, DJ; Buys, SS; Conner, T; Domchek, S; Powers, J; Ausems, MG; Teixeira, MR; Maia, S; Izatt, L; Schmutzler, R; Rhiem, K; Foulkes, WD; Boshari, T; Davidson, R; Ruijs, M; Helderman-van den Enden, AT; Andrews, L; Walker, L; Snape, K; Henderson, A; Jobson, I; Lindeman, GJ; Liljegren, A; Harris, M; Adank, MA; Kirk, J; Taylor, A; Susman, R; Chen-Shtoyerman, R; Pachter, N; Spigelman, A; Side, L; Zgajnar, J; Mora, J; Brewer, C; Gadea, N; Brady, AF; Gallagher, D; van Os, T; Donaldson, A; Stefansdottir, V; Barwell, J; James, PA; Murphy, D; Friedman, E; Nicolai, N; Greenhalgh, L; Obeid, E; Murthy, V; Copakova, L; McGrath, J; Teo, S-H; Strom, S; Kast, K; Leongamornlert, DA; Chamberlain, A; Pope, J; Newlin, AC; Aaronson, N; Ardern-Jones, A; Bangma, C; Castro, E; Dearnaley, D; Eyfjord, J; Falconer, A; Foster, CS; Gronberg, H; Hamdy, FC; Johannsson, O; Khoo, V; Lubinski, J; Grindedal, EM; McKinley, J; Shackleton, K; Mitra, AV; Moynihan, C; Rennert, G; Suri, M; Tricker, K; IMPACT study collaborators; Moss, S; Kote-Jarai, Z; Vickers, A; Lilja, H; Helfand, BT; Eeles, RA (2018-01-04)
      BACKGROUND:Prostate-specific antigen (PSA) and PSA-velocity (PSAV) have been used to identify men at risk of prostate cancer (PrCa). The IMPACT study is evaluating PSA screening in men with a known genetic predisposition ...